While CT20p has not yet been tested in clinical trials, we anticipate that cytoprotective pro-tumor effects associated with HSP90 inhibitors would not transpire given that reductions in CCT levels do not induce a heat shock response (17) and cct genes have fewer heat shock elements for binding heat shock transcription factors (HSF1 and HSF2) than comparable HSPs (6). This evidence concerns the gene HSP90AA1 and neoplasm.